Trevena Announces Initiation of Proof-of-Concept Study for TRV734 for Potential Treatment of Opioid Use Disorder
CHESTERBROOK, PA — Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, announced the initiation of a …
Read More